Member Info for DugWalker

Presumably we all invested here because we believe in the science. That's not the problem here. The issue is that after 2 years we are still counting daily CiRT sales on the digits of one hand and whilst it is early days for PSE it hasn't hit the road running either. Why is Episwitch apparently news to these precision medicine specialists? Has the corporate publicity campaign in the US flopped?

Hopefully our growing gang of Marketing and Sales VP's can take this positive publicity beyond a specialist conference audience and convert it to sales.

Not a peep Tav. Clearly don't care about their retail investors.

@Jiffy.

The technology is why I'm still invested here (albeit with a reduced holding reflecting the current risks) but it doesn't guarantee anything. Biotech is an expensive hobby to have for small cap companies and markets can be difficult to access for all sorts of reasons (including manipulation by big pharma). There's a warning in an RNS from today as to what can happen if you don't get revenues and rely on fund raises.

https://www.londonstockexchange.com/news-article/AVO/further-update-on-financing-discussions/16313052

Bottom line here is the 10% of our employees that are customer facing V.P's need to start earning their crust by selling and our CEO needs to identify and remove barriers that may be preventing them from doing so.

The safety net is that I can envisage a takeover. So at least we should see some return on investment, but it may not be as much as it should have been.

Wow. 17% spread on opening today. Way to go to encourage buyers!

hi tav,

not a thing mate. i'd post any reply i get as promised.

seems increasingly clear to.me they are determined to ignore any awkward questions. can only hope the message gets through regardless. have to say it's **** poor that our chairman is in hiding. i suspect he must be embarrassed that the cronyism he's endorsed is delivering what it is.

Have never doubted the commercial potential of the science, but I do have major issues with an overblown, rapidly expanding management team recruited by cronyism and delivering nothing that matters. Agreements with insurers don't keep the lights on unless and until our multitude of VP's start selling.

There's a placement coming imminently and a 12% spread on the ask/bid. I'll wait till the dust settles on those before investing anymore.

Who watches the BBC? Probably the majority of the population at greatest risk of bowel cancer.

Big feature item on colorectal cancer on this morning's BBC news. Another chance of free publicity goes begging whilst our US based management team focus on the 'biggest market' to accomplish a couple of tests sold per day! 5 VP's, 3 recently employed to sell and this is what we get.

Maybe we'll get an update on PSE sales following the first month of the US insurance code going live, in order to halt the slide in the SP.

....or maybe not.

Couldn't sell a lifebelt to a drowning man.

Hi Jiffy,

Yep V.P. is an abbreviation of Vice President. Sadly we have many of them, all charged with doing one another's job.

The science is good, if yet to be validated to the satisfaction of the medical community. Competent management is another thing, but it will happen in time, as I suspect we are moving headlong to a takeover. Sadly that looks like happening on the cheap.

Tav I was going to do that, but the only email address I can find for Wakefield is the black hole that is investorrelations@oxfordbiodynamics.com so would not be hopeful of a response.

Tav ,

WRT Burrows salary and work as President of Contracts Division at polarityTE (now RegenETP) I posted external links to this info earlier in the thread.

Here's another on his other part-time employment

https://finance.yahoo.com/quote/RGTPQ/profile/

The interesting thing is it confirms RegenETP as another small (42 employees) organisation top-heavy with senior managers. Almost 1 in 4 employees there are in executive posts. Where have I seen that before. Funnily enough if you scroll down the named senior managers you will find that the guy just employed to head upthe push on CiRT is also a part-timer.

GMS,

As I said once before on this thread, when the facts change I change my.mind, what do you do?

As for the paper the very last sentence in the conclusions section states

an

."Further extended prospective blinded validation of the new combined signature in a screening cohort with low cancer prevalence would be the recommended step for PSE adoption in PCa screening"

Which is pretty much what Prostate Cancer UK also say.

I suggest you do some research on Stockholm3. It hasbeen used o. Tens of thousands of men in Scandanavia. It too is a blood test and not a drug, but the UK National Screening Committee say it also needs further validation due to a lack of diversity in the ethnic groups to which it has been supplied hence it will highly probably be the candidate blood test in the Transform trial.

What I'm saying is Burrows promised exponential growth of revenues back in July and actually delivered a month on month decline by December. The cash burn will scarcely notice the incremental growth (if there is any!) That you seem to think acceptable.

Burrows is highly likely to ask for £20 million from shareholders or buyers of our IP just to keep the doors open. The Transform trial is a god sent opportunity to get the extensive validation the medical community expect, and to do so at zero cost to OBD. Budgets are currently being negotiated with the participants and the first few thousand volunteers will have been tested against the candidate tests by this time next year. Its an absolute no brainer, yet our CEO had to sit reading extracts from the Prostate Cancer UK press release in a comical attempt to appear knowledgeable.

As for BUPA I have used them on a number of occasions. When you call them to get approval to progress to a treatment the first thing they do is tell you the names of their practitioners that you can consult. They are not BUPA employees but BUPA use them as paid consultants. Oh and yes I understood from the RNS that a deal had been struck with BUPA. What it seemingly omitted to say was that we would be running workshops to try to persuade their consulting oncologists to use their tests. A bit like the failed P2P model that has delivered 'exponential growth' (or not as the case actually is).

Nothing from. IR Tav.

Hi GMS,

I think it's no surprise that when your CEO trumpets that exponential growth has been achieved that folks had expectations that sales would at least be up! We discussed this at the time and I took a modest linear growth rate of 20% per month to arrive at a target sales rate of ~200 CiRT tests per month. You thought that was too much, which is fair enough, but it's maybe fair to note that if that modest growth rate is not achieved, there is no chance of the company reaching breakeven in the coming year. That means at least 2 more placings or a sale of the family heirlooms. Reducing the asset value of the company.

The only way I can see a recovery in SP into the 20's is if Burrows is replaced, there's an acknowledgement that neither CiRT or PSE are clinically validated (as opposed to laboratory validated) and we manage to secure participation in Transform. The company cannot finance a blind randomised trial at scale, so Transform is an absolute must do.

The evidence to date is that medics are reluctant to adopt a test that even the paper in Cancers explicitly acknowledges needs further extensive validation. P2P has been a disaster and now we hear that whilst there is an agreement with BUPA the lan is to hold more workshops in an attempt to get BUPA oncologists to behave differently from their colleagues in the US.

Https://uk.marketscreener.com/insider/JON-BURROWS-A1O7E2/

Doesn't need to tout his CV to JP Morgan or anyone else hor that matter. He has been working as the President of the contract services division of PolarityTE (Aka RegenETP) from where he had recruited several of our multiple V.P.'s.

He is on £500k a year and is our part-time CEO. I'd laugh if I wasn't invested here.

It's a vanity project. According to the annual report the facility.in Penang is a lab!!!

Why on earth does a company loft 50 employees, losing circa 10 million a year and selling a couple of tests a day need 3 labs? One in the UK, one in the US and one in Asia?

Is there no financial discipline in this company? Why isn't the Chairman challenging some of these absurdities?

Hi Tav.

Can but hope.

Maybe he will also ask why we gave an office in Penang Malaysia that, according to the only numbers I have found, employs 3 people! What do they do?

This increasingly has the feel of someone's vanity project.

6 Senior managers (V.P. and above) share past employers with Burrows. 4 are V.P.'s with sales and marketing responsibilities that are very hard to differentiate from one another. In spite of this abundance of V.P.'s they struggle to sell our products.

I have been unable to find evidence of competitive recruitment processes prior to appointments.

Why do we need so many V.P.'s to accomplish sales of 1 CiRT and 1 PSE test a day? What efforts were made to ensure the incumbents were the best candidates for their roles? Do their job descriptions and KPI's help to define and differentiate their roles?

@Tav.

Predictably the answer is no. Not so much as an acknowledgement.